Differential structural and functional changes in penile and coronary arteries from obese Zucker rats.
Erectile dysfunction frequently coexists with coronary artery disease and has been proposed as a potential marker for silent coronary artery disease in type 2 diabetes. In the present study, we comparatively assessed the structural and functional changes of both penile arteries (PAs) and coronary arteries (CAs) from a prediabetic animal model. PAs and CAs from 17- to 18-wk-old obese Zucker rats (OZRs) and from their control counterparts [lean Zucker rats (LZRs)] were mounted in microvascular myographs to evaluate vascular function, and stained arteries were subjected to morphometric analysis. Endothelial nitric oxide (NO) synthase (eNOS) protein expression was also assessed. The internal diameter was reduced and the wall-to-lumen ratio was increased in PAs from OZRs, but structure was preserved in CAs. ACh-elicited relaxations were severely impaired in PAs but not in CAs from OZRs, although eNOS expression was unaltered. Contractions to norepinephrine and 5-HT were significantly enhanced in both PAs and CAs, respectively, from OZRs. Blockade of NOS abolished endothelium-dependent relaxations in PAs and CAs and potentiated norepinephrine and 5-HT contractions in arteries from LZRs but not from OZRs. The vasodilator response to the phosphodiesterase 5 inhibitor sildenafil was reduced in both PAs and CAs from OZRs. Pretreatment with SOD reduced the enhanced vasoconstriction in both PAs and CAs from OZRs but did not restore ACh-induced relaxations in PAs. In conclusion, the present results demonstrate vascular inward remodeling in PAs and a differential impairment of endothelial relaxant responses in PAs and CAs from insulin-resistant OZRs. Enhanced superoxide production and reduced basal NO activity seem to underlie the augmented vasoconstriction in both PAs and CAs. The severity of the structural and functional abnormalities in PAs might anticipate the vascular dysfunction of the more preserved coronary vascular bed.
Villalba
Nuria
N
Department of Physiology, Faculty of Pharmacy, Faculty of Veterinary Sciences, Universidad Complutense, Madrid, Spain.
Martínez
Pilar
P
Bríones
Ana Maria
AM
Sánchez
Ana
A
Salaíces
Mercedes
M
García-Sacristán
Albino
A
Hernández
Medardo
M
Benedito
Sara
S
Prieto
Dolores
D
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D001158:Arteries / Q000473:pathology / Q000502:physiology; D002784:Cholesterol / Q000097:blood; D003331:Coronary Vessels / Q000473:pathology* / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000473:pathology / Q000503:physiopathology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D007172:Erectile Dysfunction / Q000473:pathology* / Q000503:physiopathology*; D008297:Male; D009569:Nitric Oxide / Q000378:metabolism; D052250:Nitric Oxide Synthase Type III / Q000037:antagonists & inhibitors / Q000378:metabolism; D019335:Nitroarginine / Q000494:pharmacology; D009765:Obesity / Q000473:pathology / Q000503:physiopathology; D010413:Penis / Q000098:blood supply*; D010879:Piperazines / Q000494:pharmacology; D011236:Prediabetic State / Q000473:pathology* / Q000503:physiopathology*; D011687:Purines / Q000494:pharmacology; D051381:Rats; D011924:Rats, Zucker; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000494:pharmacology; D013481:Superoxides / Q000378:metabolism; D014280:Triglycerides / Q000097:blood; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology; D014665:Vasodilator Agents / Q000494:pharmacology
D004791:Enzyme Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014280:Triglycerides; D014665:Vasodilator Agents; D013481:Superoxides; D019335:Nitroarginine; D009569:Nitric Oxide; D002784:Cholesterol; D000068677:Sildenafil Citrate; D052250:Nitric Oxide Synthase Type III; C496316:Nos3 protein, rat; D000109:Acetylcholine